CD274 and non-small cell lung carcinoma: In this retrospective and multicentric study based on real-world data, the single agent pembrolizumab was shown to be beneficial as an upfront treatment in patients with advanced NSCLC with PD-L1-positive expression ≥ 50% and BM.